417 related articles for article (PubMed ID: 29190241)
21. Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration.
Marquis LM; Mantel I
Graefes Arch Clin Exp Ophthalmol; 2020 Aug; 258(8):1591-1596. PubMed ID: 32399582
[TBL] [Abstract][Full Text] [Related]
22. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
[TBL] [Abstract][Full Text] [Related]
23. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy.
Ricci F; Parravano M; Regine F; Sciamanna M; Tedeschi M; Missiroli F; Varano M
Eye (Lond); 2016 Aug; 30(8):1077-83. PubMed ID: 27229701
[TBL] [Abstract][Full Text] [Related]
24. EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial.
Mitchell P; Holz FG; Hykin P; Midena E; Souied E; Allmeier H; Lambrou G; Schmelter T; Wolf S;
Retina; 2021 Sep; 41(9):1911-1920. PubMed ID: 33782365
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal ranibizumab for the treatment of fibrovascular pigment epithelial detachment in age-related macular degeneration.
Iordanous Y; Powell AM; Mao A; Hooper PL; Eng KT; Schwartz C; Kertes PJ; Sheidow TG
Can J Ophthalmol; 2014 Aug; 49(4):367-76. PubMed ID: 25103655
[TBL] [Abstract][Full Text] [Related]
26. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
[TBL] [Abstract][Full Text] [Related]
28. Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration.
Major JC; Wykoff CC; Croft DE; Wang R; Mariani AF; Lehmann AE; Brown DM
Can J Ophthalmol; 2015 Oct; 50(5):373-7. PubMed ID: 26455973
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal aflibercept in treatment-resistant pigment epithelial detachment.
Kocak I
Int Ophthalmol; 2017 Jun; 37(3):531-537. PubMed ID: 27444307
[TBL] [Abstract][Full Text] [Related]
30. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
Kvannli L; Krohn J
Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab.
Elwes F; Borooah S; Aspinall P; Sim PY; Loo CY; Armbrecht AM; Dhillon B; Cackett P
BMC Ophthalmol; 2018 Jan; 18(1):20. PubMed ID: 29378528
[TBL] [Abstract][Full Text] [Related]
32. Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept.
Calvo-Gonzalez C; Reche-Frutos J; Fernández-Vigo JI; Donate-López J; Serrano-García I; Fernández-Pérez C
Int Ophthalmol; 2019 Nov; 39(11):2441-2448. PubMed ID: 30767090
[TBL] [Abstract][Full Text] [Related]
33. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
Jørstad ØK; Faber RT; Moe MC
Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
[TBL] [Abstract][Full Text] [Related]
34. Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration.
Dirani A; Ambresin A; Marchionno L; Decugis D; Mantel I
Am J Ophthalmol; 2015 Oct; 160(4):732-8.e2. PubMed ID: 26144701
[TBL] [Abstract][Full Text] [Related]
35. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study.
Augsburger M; Sarra GM; Imesch P
Graefes Arch Clin Exp Ophthalmol; 2019 Sep; 257(9):1889-1895. PubMed ID: 31256237
[TBL] [Abstract][Full Text] [Related]
36. Alterations of vascular pigment epithelium detachments associated with age-related macular degeneration during upload with intravitreal ranibizumab.
Wolf A; Rüping J; Neubauer AS; Mayer W; Ulbig M; Haritoglou C; Holz FG; Eter N; Kampik A
Retina; 2013 Oct; 33(9):1843-9. PubMed ID: 23598795
[TBL] [Abstract][Full Text] [Related]
37. Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept.
Chatziralli I; Nicholson L; Vrizidou E; Koutsiouki C; Menon D; Sergentanis TN; Citu MC; Hamilton R; Patel PJ; Hykin P; Sivaprasad S
Ophthalmology; 2016 Aug; 123(8):1762-1770. PubMed ID: 27289179
[TBL] [Abstract][Full Text] [Related]
38. Prospective evaluation of aflibercept in pigment epithelial detachments secondary to neovascular age related macular degeneration.
Diaconita V; Li B; Pal L; Bahnacy F; Gonder JR
Can J Ophthalmol; 2019 Oct; 54(5):626-634. PubMed ID: 31564356
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
[TBL] [Abstract][Full Text] [Related]
40. Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials.
Khurana RN; Rahimy E; Joseph WA; Saroj N; Gibson A; Vitti R; Berliner AJ; Chu K; Cheng Y; Boyer DS
Am J Ophthalmol; 2019 Apr; 200():161-168. PubMed ID: 30664844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
